Cover Image
Market Research Report

Europe Body Composition Analyzers - Industry Trends and Forecast to 2024

Published by Data Bridge Market Research Private Limited Product code 536503
Published Content info 122 Pages; 48 Tables; 31 Figures
Delivery time: 1-2 business days
Price
Back to Top
Europe Body Composition Analyzers - Industry Trends and Forecast to 2024
Published: May 20, 2017 Content info: 122 Pages; 48 Tables; 31 Figures
Description

Synopsis:

Europe Body Composition Analyzers Market is expected to reach USD 660.9 million by 2024, at a CAGR 7.8% during the forecast period of 2017 to 2024. The report contains 124 pages of exclusive premium insights with 48 tables and 31 figures.

The market has been segmented On the basis of product type into Bioimpedance Analyzer, Skinfold Caliper, Dual Emission X-Ray Absorptiometry (Dexa), Hydrostatic Weighing, Air Displacement Plethysmography.

Based on end-user the market is segmented into Private Clinics, Offices, Health Clubs, Hospitals, Others.

Based on geography the market is segmented into major countries such as Germany, France, U.K., Belgium, Switzerland, Turkey, Russia, Netherlands, Italy, and Spain.

Major Players Operating in this market:

Tanita, InBody Co., Ltd., Omron Healthcare, Inc., Jawon Medical Co., Ltd. , Bodystat , Hologic, Inc., GE Healthcare, COSMED, Beurer GmbH, and Seca among others.

Regions Covered In The Scope Of The Report:

Europe (Germany, France, U.K., Italy, Spain, Russia, Belgium, Netherlands, Switzerland, Turkey, Rest of Europe)

Table of Contents

Table of Contents

1. INTRODUCTION

  • 1.1. OVERVIEW OF THE BODY COMPOSITION ANALYZERS MARKET
  • 1.2. MARKET SEGMENTATION & COVERAGE

2. RESEARCH METHODOLOGY

  • 2.1. KEY TAKEAWAYS
  • 2.2. ARRIVING AT THE BODY COMPOSITION ANALYZERS MARKE SIZE
    • 2.2.1. MARKET CRACKDOWN APPROACH
    • 2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
    • 2.2.3. KEY DATA POINTS FROM PRIMARY SOURCE
    • 2.2.4. KEY DATA POINTS FROM SECONDARY SOURCE
    • 2.2.5. DEMAND ANALYSIS MATRIX
  • 2.3. ASSUMPTIONS

3. MARKET LANDSCAPE SUMMARY

4. MARKET OVERVIEW

  • 4.1. OVERVIEW
  • 4.2. BODY COMPOSITION ANALYZERS: KEY PRIMARY INSIGHTS
  • 4.3. DRIVERS, OPPORTUNITIES AND THREAT ANALYSIS MATRIX
  • 4.4. KEY MARKET FINDINGS
  • 4.5. NEW REGULATORY POLICIES

5. BODY COMPOSITION ANALYZERS MARKET, BY PRODUCT

  • 5.1. OVERVIEW
  • 5.2. BIOIMPEDANCE ANALYZERS (BIA)
  • 5.3. DUAL-ENERGY X-RAY ABSORPTIOMETRY (DEXA)
  • 5.4. SKINFOLD CALIPERS
  • 5.5. HYDROSTATIC WEIGHING (HWD)
  • 5.6. AIR DISPLACEMENT PLETHYSMOGRAPHY (ADP)

6. BODY COMPOSITION ANALYZERS MARKET, BY GEOGRAPHY

  • 6.1. COUNTRYWISE BODY COMPOSITION ANALYZERS MARKET, BY GEOGRAPHY (BY PRODUCT)
    • 6.1.1. EUROPE
      • 6.1.1.1. GERMANY
      • 6.1.1.2. FRANCE
      • 6.1.1.3. U.K.
      • 6.1.1.4. ITALY
      • 6.1.1.5. SPAIN
      • 6.1.1.6. RUSSIA
      • 6.1.1.7. TURKEY
      • 6.1.1.8. BELGIUM
      • 6.1.1.9. NETHERLANDS
      • 6.1.1.10. SWITZERLAND
      • 6.1.1.11. REST OF EUROPE
  • 6.2. KEY PRIMARY INSIGHTS: BY COUNTRY

7. BODY COMPOSITION ANALYZERS MARKET: COMPETITIVE LANDSCAPE

  • 7.1. BIOIMPEDENCE ANALYZERS MARKET: COMPANY SHARE
  • 7.2. EUROPE BIOIMPEDENCE ANALYZERS MARKET: COMPANY SHARE
  • 7.3. MERGERS & ACQUISITIONS
  • 7.4. NEW PRODUCT DEVELOPMENT & APPROVALS
  • 7.5. EXPANSIONS
  • 7.6. REGULATORY CHANGES
  • 7.7. PARTNERSHIP AND OTHER STRATEGIC DEVELOPEMENTS

8. BODY COMPOSITION ANALYZERS MARKET, COMPANY PROFILES

  • 8.1. TANITA
    • 8.1.1. OVERVIEW
    • 8.1.2. SWOT ANALYSIS
    • 8.1.3. PRODUCT PORTFOLIO
    • 8.1.4. REVENUE ANALYSIS
    • 8.1.5. ANALYSTS VIEW
  • 8.2. BODYSTAT
    • 8.2.1. OVERVIEW
    • 8.2.2. SWOT ANALYSIS
    • 8.2.3. PRODUCT PORTFOLIO
    • 8.2.4. REVENUE ANALYSIS
    • 8.2.5. ANALYSTS VIEW
  • 8.3. OMRON HEALTHCARE, INC.
    • 8.3.1. OVERVIEW
    • 8.3.2. SWOT ANALYSIS
    • 8.3.3. PRODUCT PORTFOLIO
    • 8.3.4. REVENUE ANALYSIS
    • 8.3.5. ANALYST VIEW
  • 8.4. JAWON MEDICAL CO., LTD.
    • 8.4.1. OVERVIEW
    • 8.4.2. SWOT ANALYSIS
    • 8.4.3. PRODUCT PORTFOLIO
    • 8.4.4. REVENUE ANALYSIS
    • 8.4.5. ANALYSTS VIEW
  • 8.5. INBODY CO. LTD
    • 8.5.1. OVERVIEW
    • 8.5.2. SWOT ANALYSIS
    • 8.5.3. PRODUCT PORTFOLIO
    • 8.5.4. REVENUE ANALYSIS
    • 8.5.5. ANALYSTS VIEW
  • 8.6. COSMED
    • 8.6.1. OVERVIEW
    • 8.6.2. SWOT ANALYSIS
    • 8.6.3. PRODUCT PORTFOLIO
    • 8.6.4. REVENUE ANALYSIS
    • 8.6.5. ANALYSTS VIEW
  • 8.7. BEURER GMBH
    • 8.7.1. OVERVIEW
    • 8.7.2. SWOT ANALYSIS
    • 8.7.3. PRODUCT PORTFOLIO
    • 8.7.4. REVENUE ANALYSIS
    • 8.7.5. ANALYSTS VIEW
  • 8.8. MALTRON INTERNATIONAL LTD
    • 8.8.1. OVERVIEW
    • 8.8.2. SWOT ANALYSIS
    • 8.8.3. PRODUCT PORTFOLIO
    • 8.8.4. REVENUE ANALYSIS
    • 8.1.5. ANALYSTS VIEW
  • 8.9. HOLOGIC, INC.
    • 8.9.1. OVERVIEW
    • 8.9.2. SWOT ANALYSIS
    • 8.9.3. PRODUCT PORTFOLIO
    • 8.9.4. REVENUE ANALYSIS
    • 8.9.5. ANALYSTS VIEW
  • 8.10. SECA
    • 8.10.1. OVERVIEW
    • 8.10.2. SWOT ANALYSIS
    • 8.10.3. PRODUCT PORTFOLIO
    • 8.10.4. REVENUE ANALYSIS
    • 8.10.5. ANALYSTS VIEW
  • 8.11. LAICA SPA
    • 8.11.1. OVERVIEW
    • 8.11.2. SWOT ANALYSIS
    • 8.11.3. PRODUCT PORTFOLIO
    • 8.11.4. REVENUE ANALYSIS
    • 8.11.5. ANALYSTS VIEW
  • 8.12. GE HEALTHCARE
    • 8.12.1. OVERVIEW
    • 8.12.2. SWOT ANALYSIS
    • 8.12.3. PRODUCT PORTFOLIO
    • 8.12.4. REVENUE ANALYSIS
    • 8.12.5. ANALYSTS VIEW
  • 8.13. RJL SYSTEMS INC
    • 8.13.1. OVERVIEW
    • 8.13.2. SWOT ANALYSIS
    • 8.13.3. PRODUCT PORTFOLIO
    • 8.13.4. REVENUE ANALYSIS
    • 8.13.5. ANALYSTS VIEW
Back to Top